Michael J. Fox was diagnosed with Parkinson's disease in 1991 and went public with it in 1998. Two years later he launched The Michael J. Fox Foundation for Parkinson's Research with a blunt ambition that still defines it: to fund the science that would make the foundation itself unnecessary. For more than two decades the central frustration has been that there was no objective test to confirm Parkinson's in a living person.
In April 2023 the foundation announced that this had changed. Working through its Parkinson's Progression Markers Initiative, a long-running study known as PPMI, an international team validated a tool called the alpha-synuclein seeding amplification assay, or aSyn-SAA. The assay detects abnormal alpha-synuclein, often described as the Parkinson's protein, in a sample of spinal fluid, and the results were published in the journal The Lancet Neurology.
The numbers reported were striking. According to the foundation's announcement, the assay correctly identified abnormal alpha-synuclein in about 93 percent of participants who had Parkinson's, while flagging the protein in fewer than 5 percent of people without the disease. Crucially, it could detect the pathology in some people who had not yet been diagnosed or had not yet shown clinical symptoms, raising the prospect of catching the disease earlier than clinical observation allows.
The analysis was large by the standards of the field. The foundation described a cohort of more than 1,100 PPMI participants, and noted that results varied across genetic forms of the disease, with higher detection rates in people carrying certain gene variants than others. That variation is itself useful information for designing trials around specific patient subgroups.
Why does a test matter so much? Parkinson's has long been diagnosed by watching symptoms emerge, which means that by the time a doctor is confident, substantial damage has already occurred. A biological marker lets researchers define the disease by what is happening in the body rather than only by how it looks, sort patients for clinical trials, and measure whether an experimental drug is actually changing the underlying biology.
It is important to be precise about what the 2023 announcement was and was not. It was a major research validation, widely described as the most significant development in Parkinson's research in years. It was not, on its own, a finished consumer diagnostic sitting in every neurologist's office, and the summary from the academic partners framed it as a powerful analysis of the assay's potential. The path from a validated research assay to routine clinical use is real work that follows, not a formality.
For Fox, whose foundation has channeled enormous sums into this question, the finding is the closest thing yet to vindication of the long game. For patients and families, the meaningful details, current status, what the test can be used for today, and how to take part in studies like PPMI, are best taken straight from The Michael J. Fox Foundation, which coordinates the research and keeps that information current. Confirm specifics there before acting on them.
Source date: April 13, 2023. Contextual photograph; it does not depict the people or the specific event described in this article. Photo: U.S. Marine Corps photo by Staff Sgt. Sean Potter, Public domain ↗.
Sources & further reading
This article is editorial coverage, not an endorsement. For donations or programme participation, go directly to the organization’s official website.
